Physician profile
Amit K Gupta
NPI 1114252475
$9,849.14
in general payments reported to CMS, 2019-2025
42 companies · $625 in 2025
The $625 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $3,212 · 2021: $2,201 · 2022: $842 · 2023: $1,237 · 2024: $335 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,027.73 | 2019-2025 | Peripheral Rotalink Plus, Opticross 35 |
| Penumbra, INC. | $1,416.92 | 2020-2025 | Indigo System |
| Abbott Laboratories | $669.69 | 2020-2024 | Mitraclip, Supera, Diamondback Peripheral |
| Novartis Pharmaceuticals Corporation | $640.65 | 2019-2022 | |
| Abiomed | $511.75 | 2020 | |
| Edwards Lifesciences Corporation | $463.26 | 2021-2025 | Sapien 3 Ultra Resilia, Konect Resilia |
| Janssen Pharmaceuticals, INC | $414.12 | 2019-2022 | |
| Amgen INC. | $337.68 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $321.13 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $316.02 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $293.67 | 2023 | Rotarexs 6 F X 135 Cm |
| Bayer Healthcare Pharmaceuticals INC. | $206.02 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.73 | 2020-2022 | |
| Shockwave Medical, INC | $182.87 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $179.78 | 2020-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $157.78 | 2019-2021 | |
| Philips North America LLC | $144.26 | 2020-2025 | Ecc Solutions |
| Novo Nordisk INC | $124.78 | 2021-2022 | |
| Angiodynamics, INC. | $122.62 | 2021-2023 | Auryon Laser System 100-120 Vac |
| Esperion Therapeutics, INC. | $119.02 | 2020-2022 | |
| Stryker Corporation | $116.67 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $95.49 | 2021-2022 | |
| Medtronic, INC. | $94.81 | 2021-2025 | Onyx Frontier |
| Terumo Medical Corporation | $91.35 | 2022-2023 | Glidesheath Slender, R2p Misago, Metacross Otw |
| Cardiovascular Systems INC. | $91.03 | 2020-2021 | |
| Avinger INC. | $77.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $60.52 | 2020 | |
| Inari Medical, INC. | $60.47 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bardy Diagnostics, INC. | $57.50 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $38.33 | 2021-2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $34.73 | 2021 | |
| Braemar Manufacturing, LLC | $28.67 | 2019 | |
| Allergan, INC. | $28.23 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.50 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $17.08 | 2022 | |
| Relievant Medsystems, INC. | $15.53 | 2022 | |
| Chiesi USA, INC. | $15.09 | 2020 | |
| Medtronic Vascular, INC. | $13.73 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.88 | 2021 | |
| United Therapeutics Corporation | $12.81 | 2021 | |
| Cardiva Medical, INC. | $11.75 | 2021 | |
| Celonova Biosciences, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.